Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
DMGGF$0.27-0.02(-7.78%)DMG Blockchain Solutions Issues Statement Regarding the Binance Security Incident and Provides Update on Patents Granted[12:31:27 AM ET]OFRM$15.02-0.95(-5.95%)Once Upon a Farm Announces Recall and Reformulation of Tractor Wheels™ Due to Potential Choking Hazard[10:37:00 PM ET]FANCF$0.42-0.02(-3.99%)First Atlantic to Acquire 100% of the North Arm Project, 52 sq km of Mantle-Derived Ultramafic Rocks in Western Newfoundland Never Systematically Tested for Geologic Hydrogen, Chromium or Awaruite Nickel-Cobalt Alloy[8:30:00 PM ET]NEXNF$0.09-0.00(-2.45%)NEXE Innovations Reports Q1 Fiscal 2027 Results and Business Update[8:03:56 PM ET]UREKF$0.120.00(0.00%)Eureka Metals Corp. Announces Rights Offering and Proposed Share Consolidation[7:57:00 PM ET]RMBI$15.860.00(0.00%)RICHMOND MUTUAL BANCORPORATION, INC. ANNOUNCES 2026 THIRD QUARTER FINANCIAL RESULTS Richmond Mutual Bancorporation, Inc., a Maryland corporation (the "Company") (NASDAQ: RMBI), parent company of First Bank Midwest, today reported net ...[7:55:00 PM ET]MVLY$21.69+0.73(+3.48%)Mission Valley Bancorp Reports Third Quarter Results[7:52:00 PM ET]UNIB$21.350.00(0.00%)University Bancorp Closes on the Acquisition of 20% of UIF Corporation for Cash & Stock Worth About $15.2 Million[7:45:00 PM ET]NXTT$5.02+0.17(+3.51%)Next Technology Holding Inc. Announces Board Authorization to Sell or Pledge of Bitcoin Holdings to Reduce Bitcoin Exposure and Enhance Liquidity[7:20:00 PM ET]PRRSF$0.04+0.00(+10.13%)Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement[6:35:00 PM ET]OTAI$10.11+0.00(+0.05%)Spider Digital Technology Ltd. and Starlink AI Acquisition Corporation Announce Definitive Business Combination Agreement[6:30:00 PM ET]

AURA · NASDAQ

Aura Biosciences, Inc.

$6.14 -0.15 (-2.38%)

Company overview

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops a virus-like drug conjugates (VDC) technology platform for treating tumors with high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$637M
Employees
106
Headquarters
Boston, MA
Website
aurabiosciences.com
CEO
Elisabet de los Pinos
Listed
October 29, 2021
P/E
-3.47
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$574,000
Operating income
-$119M
EBITDA
-$116M
Net income
-$112M
EPS
-$1.77
Total assets
$138M
Total debt
$17M
Earnings yield
-28.83%

Price chart

5.816.777.748.719.68
AURA 1D NASDAQ O6.43H6.43L6.04C6.15-0.15 (-2.38%)Vol78.18K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
AURAAura Biosciences, Inc. Stock news Aura Biosciences: A Pivotal Trial Engineered With Room To Spare Seeking Alpha
AURAAura Biosciences, Inc. Press release Auranova Announces Closing of Private Placement of Units and Flow-Through Shares Newsfile
AURAAura Biosciences, Inc. Stock news Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
AURAAura Biosciences, Inc. Press release Aura Biosciences to Participate in Upcoming Investor Conference GlobeNewswire
AURAAura Biosciences, Inc. Press release Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
AURAAura Biosciences, Inc. Stock news ADAR1 Capital Management LLC Acquires Shares of 130,152 Aura Biosciences, Inc. $AURA Defense World
AURAAura Biosciences, Inc. Stock news Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval Seeking Alpha
AURAAura Biosciences, Inc. Stock news Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday's Pre-Market Session Benzinga
AURAAura Biosciences, Inc. Press release Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors GlobeNewsWire
AURAAura Biosciences, Inc. Press release Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma GlobeNewsWire
AURAAura Biosciences, Inc. Stock news Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances MarketBeat
AURAAura Biosciences, Inc. Stock news Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data MarketBeat
AURAAura Biosciences, Inc. Press release Aura Biosciences to Participate in Upcoming Investor Conferences GlobeNewsWire
AURAAura Biosciences, Inc. Press release Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights GlobeNewsWire
AURAAura Biosciences, Inc. Press release AMG Reports Better than Expected First Quarter 2026 Results GlobeNewsWire
AURAAura Biosciences, Inc. Press release Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewsWire
AURAAura Biosciences, Inc. Press release Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants GlobeNewsWire
AURAAura Biosciences, Inc. Stock news Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Globe News Wire
AURAAura Biosciences, Inc. Press release Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GlobeNewsWire
AURAAura Biosciences, Inc. Press release Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion GlobeNewsWire
See more
FAQ

Questions about Aura Biosciences, Inc.

What does Aura Biosciences, Inc. do?
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops a virus-like drug conjugates (VDC) technology platform for treating tumors with high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
What is AURA's market cap?
Aura Biosciences, Inc. (AURA) is a listed stock with a live quote. The latest market cap on this page is $637M.
Where is Aura Biosciences, Inc. headquartered?
Aura Biosciences, Inc. is headquartered in Boston, MA.
How do I get AURA news from the API?
Call GET /v1/news?tickers=AURA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does AURA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for AURA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the AURA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs